Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Angiogenesis - still a worthwhile target for breast cancer therapy?

Lord S. and Harris AL., (2010), Breast Cancer Res, 12 Suppl 4

Thyrotoxicosis with pegylated interferon alfa-2b.

Lowndes SA. et al, (2010), Arch Dermatol, 146, 1273 - 1275

A phase 2 study of vatalanib in metastatic melanoma patients.

Cook N. et al, (2010), Eur J Cancer, 46, 2671 - 2673

A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer.

Sabharwal A. et al, (2010), Cancer Chemother Pharmacol, 66, 829 - 835

Persistent malignant stem cells in del(5q) myelodysplasia in remission.

Tehranchi R. et al, (2010), N Engl J Med, 363, 1025 - 1037

ROLE OF BIALLELIC C/EBPALPHA MUTATIONS AND FLT-3 ITD IN INITIATION AND MAINTENANCE OF AML

Reckzeh K. et al, (2010), EXPERIMENTAL HEMATOLOGY, 38, S116 - S117

The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration.

Burrows C. et al, (2010), Nucleic Acids Res, 38, 5542 - 5553

Stability of measurement of the immature platelet fraction.

Ruisi MM. et al, (2010), Am J Hematol, 85, 622 - 624

Quinone oxidoreductase-2-mediated prodrug cancer therapy.

Middleton MR. et al, (2010), Sci Transl Med, 2